Cargando…

Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study

OBJECTIVE: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. METHODS: In this retrospective cohort study (GSK Study 213061)...

Descripción completa

Detalles Bibliográficos
Autores principales: DerSarkissian, Maral, Gu, Yuqian M., Duh, Mei Sheng, Benson, John, Huang, Shirley P., Averell, Carlyne, Vu, Jensen, Wang, Min‐Jung, Bell, Christopher F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267805/
https://www.ncbi.nlm.nih.gov/pubmed/37226045
http://dx.doi.org/10.1002/acr2.11550
_version_ 1785059004094873600
author DerSarkissian, Maral
Gu, Yuqian M.
Duh, Mei Sheng
Benson, John
Huang, Shirley P.
Averell, Carlyne
Vu, Jensen
Wang, Min‐Jung
Bell, Christopher F.
author_facet DerSarkissian, Maral
Gu, Yuqian M.
Duh, Mei Sheng
Benson, John
Huang, Shirley P.
Averell, Carlyne
Vu, Jensen
Wang, Min‐Jung
Bell, Christopher F.
author_sort DerSarkissian, Maral
collection PubMed
description OBJECTIVE: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. METHODS: In this retrospective cohort study (GSK Study 213061), eligible patients (aged ≥5 years at first OCS claim) with SLE from the IQVIA Real‐World Data Adjudicated Claims‐US database (January 2006 to July 2019) had continuous enrollment during the 6‐month preindex (baseline) and 12‐month postindex (observation) periods and one or more inpatient or emergency department SLE diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. The “OCS‐initiator cohort” comprised patients with one or more OCS pharmacy claims during the study period and no evidence of preindex OCS use and was classified into three exposure categories based on the number of 6‐month periods of more than 5 mg/day of OCS use (0, 1, 2). The “no‐OCS‐use cohort” comprised patients without OCS claims, although patients may have received OCS prior to the study period. Clinical and economic outcomes were reported over the observation period. RESULTS: Adjusted health care costs differed significantly ($6542 [95% confidence interval (CI): $5761‐$7368], $19,149 [95% CI: $16,954‐$21,471], $28,985 [95% CI: $25,546‐$32,885]). HCRU incidence rates were significantly greater for all OCS‐initiator exposure categories (n = 16,216) versus the no‐OCS‐use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 [1.19‐1.24], 1.39 [1.34‐1.43], 1.66 [1.60‐1.73]). OCS‐related AEs were experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly affecting the immune system. CONCLUSION: Within 12 months of OCS initiation, patients with SLE experienced substantial clinical and economic burden, which may imply a need to minimize OCS use.
format Online
Article
Text
id pubmed-10267805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-102678052023-06-15 Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study DerSarkissian, Maral Gu, Yuqian M. Duh, Mei Sheng Benson, John Huang, Shirley P. Averell, Carlyne Vu, Jensen Wang, Min‐Jung Bell, Christopher F. ACR Open Rheumatol Original Articles OBJECTIVE: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. METHODS: In this retrospective cohort study (GSK Study 213061), eligible patients (aged ≥5 years at first OCS claim) with SLE from the IQVIA Real‐World Data Adjudicated Claims‐US database (January 2006 to July 2019) had continuous enrollment during the 6‐month preindex (baseline) and 12‐month postindex (observation) periods and one or more inpatient or emergency department SLE diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. The “OCS‐initiator cohort” comprised patients with one or more OCS pharmacy claims during the study period and no evidence of preindex OCS use and was classified into three exposure categories based on the number of 6‐month periods of more than 5 mg/day of OCS use (0, 1, 2). The “no‐OCS‐use cohort” comprised patients without OCS claims, although patients may have received OCS prior to the study period. Clinical and economic outcomes were reported over the observation period. RESULTS: Adjusted health care costs differed significantly ($6542 [95% confidence interval (CI): $5761‐$7368], $19,149 [95% CI: $16,954‐$21,471], $28,985 [95% CI: $25,546‐$32,885]). HCRU incidence rates were significantly greater for all OCS‐initiator exposure categories (n = 16,216) versus the no‐OCS‐use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 [1.19‐1.24], 1.39 [1.34‐1.43], 1.66 [1.60‐1.73]). OCS‐related AEs were experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly affecting the immune system. CONCLUSION: Within 12 months of OCS initiation, patients with SLE experienced substantial clinical and economic burden, which may imply a need to minimize OCS use. Wiley Periodicals, Inc. 2023-05-24 /pmc/articles/PMC10267805/ /pubmed/37226045 http://dx.doi.org/10.1002/acr2.11550 Text en © 2023 GSK and The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
DerSarkissian, Maral
Gu, Yuqian M.
Duh, Mei Sheng
Benson, John
Huang, Shirley P.
Averell, Carlyne
Vu, Jensen
Wang, Min‐Jung
Bell, Christopher F.
Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
title Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
title_full Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
title_fullStr Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
title_full_unstemmed Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
title_short Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
title_sort clinical and economic burden in patients with systemic lupus erythematosus during the first year after initiating oral corticosteroids: a retrospective us database study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267805/
https://www.ncbi.nlm.nih.gov/pubmed/37226045
http://dx.doi.org/10.1002/acr2.11550
work_keys_str_mv AT dersarkissianmaral clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT guyuqianm clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT duhmeisheng clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT bensonjohn clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT huangshirleyp clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT averellcarlyne clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT vujensen clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT wangminjung clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy
AT bellchristopherf clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy